[Nirmatrelvir/ritonavir (COVID-19) - Benefit assessment acc. to § 35a Social Code Book V]

Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018004315
Original Title: Nirmatrelvir/Ritonavir (COVID-19)
Project Status: Completed
Year Published: 2022
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • COVID-19
  • COVID-19 Drug Treatment
  • SARS-CoV-2
  • Coronavirus Infections
  • Ritonavir
  • Antiviral Agents
  • Drug Combinations
  • Nirmatrelvir
  • Ritonavir
  • COVID-19
  • Benefit Assessment
  • NCT04960202
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.